European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 144, Issue 2 , Pages 140-145 , June 2009

Examination of a first-trimester Down syndrome screening concept on a mix of 11,107 high- and low-risk patients at a private center for prenatal medicine in Germany

  • Michael Schaelike

      Affiliations

    • Center for Prenatal Diagnosis and Genetics, Bankgasse 3, D-90402 Nuremberg, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 911 2061010; fax: +49 911 2061012.
    • ,
  • Maria Kossakiewicz

      Affiliations

    • Center for Prenatal Diagnosis and Genetics, Bankgasse 3, D-90402 Nuremberg, Germany
    • ,
  • Andreas Kossakiewicz

      Affiliations

    • Center for Prenatal Diagnosis and Genetics, Bankgasse 3, D-90402 Nuremberg, Germany
    • ,
  • Ralf L. Schild

      Affiliations

    • Division of Obstetrics and Perinatal Medicine, Women's University Hospital, Universitaetsstrasse 21-23, 91054 Erlangen, Germany

Received 31 October 2007 ,Revised 13 January 2009 ,Accepted 2 March 2009.

References 

  1. Norgaard-Pedersen B, Larsen SO, Arends J, Svenstrup B, Tabor A. Maternal serum markers in screening for Down's syndrome. Clin Genet. 1990;37:35–43
  2. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med. 1998;338:955–961
  3. Nicolaides KH, Brizot ML, Snijders RJ. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy. Br J Obstet Gynaecol. 1994;101:782–786
  4. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicenter project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First-Trimester Screening Group. Lancet. 1998;352:343–346
  5. Orlandi F, Damiani G, Hallahan TW, Krantz DA, Macri JN. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol. 1997;10:381–386
  6. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn. 1997;17:821–829
  7. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol. 2000;107:1271–1275
  8. The Fetal Medicine Foundation [homepage on the Internet]. London: The Fetal Medicine Foundation, Registered Charity; c2000–06 [updated October 20, 2006; cited November 11, 2006]. Available from: http://www.fetalmedicine.com/f-downs.htm.
  9. Snijders RJ, Johnson S, Sebire NJ, Noble PL, Nicolaides KH. First-trimester ultrasound screening for chromosomal defects. Ultrasound Obstet Gynecol. 1996;7:216–226
  10. Spencer K, Nicolaides KH. A first-trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A. Prenat Diagn. 2002;22:877–879
  11. Zhang DD, Zhou XH, Freeman DH, Freeman JL. A non-parametric method for the comparison of partial areas under ROC curves and its application to large health care data sets. Stat Med. 2002;21:701–715
  12. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med. 2005;353:2001–2011
  13. Muller F, Benattar C, Audibert F, Roussel N, Dreux S, Cuckle H. First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. Prenat Diagn. 2003;23:833–836
  14. Federal Statistical Office. Statistical yearbook 2006. Federal Statistical Office, Wiesbaden, Germany; 2006. p. 52.
  15. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol. 2005;25:221–226
  16. Perni SC, Predanic M, Kalish RB, Chervenak FA, Chasen ST. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials. Am J Obstet Gynecol. 2006;194:127–130
  17. Von Kaisenberg CS, Gasiorek-Wiens A, Bielicki M, et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11–14 weeks: a German multicenter study. J Matern Fetal Neonat Med. 2002;12:89–94
  18. Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol. 1999;13:167–170

PII: S0301-2115(09)00200-0

doi: 10.1016/j.ejogrb.2009.03.007

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 144, Issue 2 , Pages 140-145 , June 2009

Article Tools

* Image Usage & Resolution